Raymond James Financial’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Raymond James Financial's AXSM Position: Q3 2026 in Review
Raymond James Financial reduced its Axsome Therapeutics (AXSM) stake by 32% in Q3 2026, selling an estimated $10.9M and leaving 105,806 shares worth $19.5M. The position accounts for 0.01% of the portfolio, ranked #1562.
Raymond James Financial first reported a position in AXSM in Q4 2024 and has held it in 8 quarters since. The position peaked at $38.1M in Q2 2026. 465 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Raymond James Financial held 105,806 shares of Axsome Therapeutics worth $19.5M as of Q3 2026.
- Raymond James Financial sold 50,049 Axsome Therapeutics shares in Q3 2026, an estimated $10.9M.
- Axsome Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q3 2026, its #1562 holding.
- Raymond James Financial first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 8 quarters since.
- Raymond James Financial's Axsome Therapeutics position peaked at $38.1M in Q2 2026.
- 465 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.